ZVSA
ZyVersa Therapeutics, Inc.Company Information
- Company Name
- ZyVersa Therapeutics, Inc.
- CIK
- CIK0001859007
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- ZVSA: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ZVSA
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- —
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2025-09-30
- Institutional shares owned
- 7
- Shares outstanding
- 7,740,678
- Ownership
- 0.00%
Earnings Market Reaction
- Filing date
- 2026-05-13
- Price on filing date
- —
- 1-month reaction
- 11.11%
- 3-month reaction
- -43.89%
Balance Sheet
Values in millions ($)| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash | 0 | 0 | 1 | 0 | 2 | 2 | 0 | 0 | 2 | 3 | 2 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | ||||||
| Deposits Assets Current | - | 0 | 0 | 0 | - | - | - | - | - | - | - | - | ||||||
| Assets Current | 1 | 0 | 1 | 1 | 2 | 2 | 0 | 1 | 3 | 3 | 2 | 1 | ||||||
| Property Plant And Equipment Net | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Intangible Assets Net Excluding Goodwill | - | - | - | - | - | - | - | - | - | - | 31 | - | ||||||
| Other Assets Noncurrent | - | - | - | - | 19 | 19 | 19 | 19 | 19 | 19 | - | 31 | ||||||
| Security Deposit | - | - | - | - | - | - | - | - | - | 0 | - | - | ||||||
| Operating Lease Right Of Use Asset | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Deferred Tax Assets In Process Research And Development | - | - | - | 19 | - | - | - | - | - | - | - | - | ||||||
| Deposits Assets Noncurrent | - | - | - | 0 | - | 0 | - | - | - | - | - | - | ||||||
| Deferred Costs | - | - | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | ||||||
| Assets | 1 | 0 | 1 | 20 | 21 | 21 | 19 | 19 | 22 | 22 | 33 | 32 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 8 | 8 | 8 | 9 | 8 | ||||||
| Accrued Liabilities Current | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 1 | 2 | 3 | 2 | ||||||
| Operating Lease Liability Current | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Convertible Notes Payable Current | 1 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities Current | 15 | 13 | 13 | 13 | 12 | 11 | 12 | 10 | 10 | 10 | 12 | 10 | ||||||
| Deferred Income Tax Liabilities Net | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities | 15 | 13 | 13 | 14 | 13 | 12 | 12 | 11 | 10 | 11 | 13 | 12 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 125 | 125 | 125 | 123 | 123 | 121 | 118 | 117 | 117 | 114 | 110 | 107 | ||||||
| Preferred Stock Value | - | - | - | - | - | - | - | - | - | 0 | - | - | ||||||
| Retained Earnings Accumulated Deficit | -139 | -138 | -137 | -117 | -115 | -113 | -111 | -109 | -106 | -103 | -90 | -87 | ||||||
| Treasury Stock Value | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Stockholders Equity | -14 | -12 | -12 | 6 | 8 | 9 | 7 | 9 | 11 | 11 | 20 | 20 | ||||||
| Liabilities And Stockholders Equity | 1 | 0 | 1 | 20 | 21 | 21 | 19 | 19 | 22 | 22 | 33 | 32 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Temporary Equity Shares Outstanding | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 110 | 110 | 110 | ||||||
| Common Stock Shares Issued | 8 | 8 | 8 | 5 | 3 | 3 | 1 | 1 | 1 | 0 | 44 | 24 | ||||||
| Shares Outstanding | 8 | 8 | 8 | 5 | 3 | 3 | 1 | 1 | 1 | 0 | 44 | 24 | ||||||
| Treasury Stock Common Shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialZyVersa Therapeutics, Inc. (ZVSA) — SEC Financial Statements & Analysis
ZyVersa Therapeutics, Inc. (ZVSA) is a pharmaceutical preparations company, incorporated in DE. ZyVersa Therapeutics, Inc. trades on OTC as: ZVSA. ZyVersa Therapeutics, Inc. (ZVSA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-13. Based on that filing, ZyVersa Therapeutics, Inc. carries a market cap of $1.62M, a P/E ratio of -0.07x, a P/B ratio of -0.11x, an enterprise value of $2.52M, and an EV/EBITDA multiple of -0.10x. On profitability, it posts a Return on Equity (ROE) of 817.12%, a Return on Assets (ROA) of -225.42%, and a Return on Invested Capital (ROIC) of -106.62%. Per share, it reports EPS of $-3.02, diluted EPS of $-3.02, free cash flow per share of $-0.51, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 176.91% year-over-year and EPS growth of 6.27% year-over-year. On the balance sheet, it maintains a current ratio of 0.05x, a quick ratio of 0.02x, working capital of $-14.12M, a debt-to-equity ratio of -1.05x, a debt ratio of 20.03, an interest coverage ratio of -46.85x, free cash flow of $-4.14M (TTM), and net debt of $897.34K. Figures sourced from SEC EDGAR.
- Market Cap
- $1.62M
- P/E TTM
- -0.07x
- EPS TTM
- $-3.02
- P/B TTM
- -0.11x
- ROE TTM
- 817.12%
- ROA TTM
- -225.42%
- Debt To Equity
- -1.05x
- Free Cash Flow TTM
- $-4.14M
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ZyVersa Therapeutics, Inc. in?
ZyVersa Therapeutics, Inc. (ZVSA) operates in the Pharmaceutical Preparations industry.
What exchange does ZVSA trade on?
ZyVersa Therapeutics, Inc. (ZVSA) trades on the OTC.
Where is ZyVersa Therapeutics, Inc. incorporated?
ZyVersa Therapeutics, Inc. is incorporated in DE.
When was ZyVersa Therapeutics, Inc. (ZVSA)'s most recent SEC filing?
ZyVersa Therapeutics, Inc. (ZVSA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-13.
What is ZVSA's market cap?
ZyVersa Therapeutics, Inc. (ZVSA) has a market capitalization of $1.62M as of 2026-03-31.
What is ZVSA's EPS (earnings per share)?
ZyVersa Therapeutics, Inc. (ZVSA)'s trailing twelve month EPS is $-3.02 as of 2026-03-31.
What is ZVSA's ROE (return on equity)?
ZyVersa Therapeutics, Inc. (ZVSA)'s trailing twelve month Return on Equity (ROE) is 817.12% as of 2026-03-31.
What is ZVSA's ROA (return on assets)?
ZyVersa Therapeutics, Inc. (ZVSA)'s trailing twelve month Return on Assets (ROA) is -225.42% as of 2026-03-31.
What is ZVSA's ROIC (return on invested capital)?
ZyVersa Therapeutics, Inc. (ZVSA)'s trailing twelve month Return on Invested Capital (ROIC) is -106.62% as of 2025-06-30.
What is ZVSA's EV/EBITDA?
ZyVersa Therapeutics, Inc. (ZVSA)'s trailing twelve month EV/EBITDA is -0.10x as of 2026-03-31.